Results:
Forty-nine patients of African descent participated in AFFIRM (n=10) or SENTINEL (n=39). Demographic and baseline disease characteristics were similar between patients treated with natalizumab (n=21) or placebo (n=28). Natalizumab therapy significantly reduced the annualized MS relapse rate by 60% (0.21 vs 0.53 in the placebo group, P=.02). Compared with placebo use, natalizumab therapy also significantly reduced the accumulation of lesions observed on magnetic resonance imaging over 2 years: the mean number of gadolinium-enhancing lesions was reduced by 79% (0.19 vs 0.91, P=.03), and the mean number of new or enlarged T2-weighted lesions was reduced by 90% (0.88 vs 8.52, P=.008).
Conclusion: Natalizumab therapy significantly improved the relapse rate and accumulation of brain lesions in patients of African descent with relapsing MS.
Arch Neurol. 2011; 68(4) : [464] [465] [466] [467] [468] P ATIENTS WITH MULTIPLE SCLErosis (MS) who are of African descent may experience a more aggressive disease course than patients who are of white race/ethnicity. Patients of African descent tend to have more frequent relapses, worse postrelapse recoveries, faster transition from relapsing remitting to secondary progressive MS, and more rapid accumulation of ambulatory disability. [1] [2] [3] [4] [5] Genetic factors seem to at least partially influence susceptibility to MS and modify the disease course. [5] [6] [7] In addition, the response to treatment with interferon beta-1a seems attenuated in this population. 5 Clinically important differences may exist between patients of African descent and patients of white race/ ethnicity with respect to treatment response. The apparently diminished treatment response in patients of African descent with MS could be due to differences in the natural history of the disease, including environmental and genetic factors, differential responses to treatment, or a combination of these variables.
In the pivotal Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) and Safety and Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing Remitting Multiple Sclerosis (SENTINEL) trials, natalizumab was shown to be effective as monotherapy 8, 9 and in combination with interferon beta-1a 10 in large diverse groups of patients with relapsing MS. The objectives of this meta-analysis were to assess the efficacy of natalizumab use in patients of African descent with relapsing MS who participated in these studies and to determine if the efficacy in this subgroup was comparable with that in the overall study population.
METHODS
Patients of African descent who participated in the AFFIRM 8, 9 or SENTINEL 10 trial were included in this post hoc analysis; the inclusion criteria for these phase 3 studies were previously published. In the AFFIRM trial, the study population was randomized 2:1 to receive natalizumab (300 mg) or placebo by intravenous infusion once every 4 weeks for up to 116 weeks. In the SENTINEL trial, the study population was randomized to receive natalizumab (300 mg) or placebo by intravenous infusion once every 4 weeks plus intramuscular interferon beta-1a (30 µg) once weekly for up to 116 weeks. Analyses were performed among patients of African descent who participated in these studies and who at screening identified their racial/ethnic origin as "black."
To achieve adequate patient numbers for analysis, data from the 2 studies were combined. Hence, the placebo group consists of patients randomized to placebo in AFFIRM and to placebo plus intramuscular interferon beta-1a in SENTINEL, while the natalizumab-treated group consists of patients randomized to natalizumab monotherapy in AFFIRM and to natalizumab plus intramuscular interferon beta-1a in SENTINEL. "Study" was excluded as a stratification factor for analyses because sample sizes were too small to investigate differences in results between the 2 trials.
Treatment effects on the following efficacy end points at 2 years were assessed: annualized relapse rate (ARR), time from first dose to first relapse, number of new or enlarged T2-weighted lesions, number of gadolinium-enhancing lesions, changes in T1-weighted and T2-weighted lesion volumes, change in Expanded Disability Status Scale (EDSS) score from baseline, and time from first dose to sustained disability progression (defined as a Ն1.0-point increase in EDSS from a baseline EDSS of Ն1.0 or a Ն1.5-point increase in EDSS from a baseline EDSS of 0, sustained for 12 weeks or 24 weeks). Magnetic resonance imaging measurements were assessed at the Central MRI Analysis Center at the Institute of Neurology, University College London, London, England. 8, 10 The following statistical analysis methods were used for each end point. The statistical models included the same covariates as were used in the previous analyses. The ARR was analyzed using Poisson regression with overdispersion adjusted for the number of relapses in the year before study enrollment, baseline EDSS (Յ3.5 vs Ͼ3.5), presence of gadolinium-enhancing lesions at baseline, and age (Ͻ40 vs Ն40 years). The time from first dose to first relapse was analyzed using a Cox proportional hazards model adjusted for the number of relapses in the year before study enrollment. A rank-based analysis of covariance was used to compare changes in T2-weighted and T1-weighted lesion volume over 2 years, number of new or enlarged T2-weighted lesions over 2 years, number of gadoliniumenhancing lesions at 2 years, and change in EDSS from baseline at 2 years. Each model was adjusted for the corresponding baseline value. Missing data were not imputed. The time from first dose to sustained (12 week and 24 week) disability progression was analyzed using a Cox proportional hazards model adjusted for baseline EDSS and age (Ͻ40 vs Ն40 years).
One of us (A.L.P.) performed the statistical analysis using commercially available software (SAS Institute Inc, Cary, North Carolina). Biogen Idec provided files containing all data described herein to the UCSF Multiple Sclerosis Center. Another of us (B.A.C.C.) verified the results by performing a replication statistical analysis with this data set using a different software program (STATA, version 9.0; StataCorp LP, College Station, Texas). 
PATIENTS
Forty-nine patients of African descent participated in either study: 6 patients from the AFFIRM study and 22 patients from the SENTINEL study were in the placebo arms, and 4 patients from the AFFIRM study and 17 patients from the SENTINEL study were in the natalizumab-treated arms. Of 49 patients, 36 patients (73%) completed the studies; 13 patients (27%) withdrew (7 from the placebo arm and 6 from the natalizumab-treated arm). Two patients (1 from each treatment arm) discontinued the study drug but completed the study follow-up. Demographic and baseline disease characteristics are given in Table 1 . Overall, the 2 study arms were fairly well matched at baseline, but some slight imbalances caused by randomization were not stratified by race/ethnicity. Patients in the placebo arm showed a trend toward more relapses in the year before study enrollment than participants in the natalizumab-treated arm. Placebo patients also had a higher median baseline T1-weighted hypointense lesion volume. Because important baseline factors were included in the statistical models to assess treatment effect, all inferences were adjusted for baseline imbalances.
EFFECT OF NATALIZUMAB USE ON RELAPSES
Natalizumab therapy significantly reduced the ARR over 2 years compared with placebo. The unadjusted ARR was 63% lowerinthenatalizumab-treatedgroup(0.80vs0.30,P=.01). After adjusting for baseline covariates, the treatment effect remained significant ( Figure 1A) . Natalizumab therapy also significantly reduced the risk of first relapse by 68% over 2 years compared with placebo ( Figure 1B) .
EFFECT OF NATALIZUMAB USE ON MAGNETIC RESONANCE IMAGING OUTCOMES
Natalizumab therapy had a significant effect on magnetic resonance imaging outcomes over 2 years in patients of African descent ( Table 2) . Natalizumab use significantly reduced the mean number of new or enlarged T2-weighted lesions over 2 years by 90% and the mean number of gadolinium-enhancing lesions at 2 years by 79% compared with placebo. Natalizumab therapy also significantly reduced changes in T2-weighted and T1-weighted lesion volume over 2 years compared with placebo (Figure 2) .
COMPARISON OF AFRICAN WITH NONAFRICAN DESCENDED PATIENTS
In Table 3 , the relative effects of natalizumab use on relapses and magnetic resonance imaging outcomes in participants of African descent vs non-African descent are compared among the present study, AFFIRM, and SENTINEL. Similar results were found when the participants of non-African descent were restricted to those of white race/ethnicity (data not shown).
EFFECT OF NATALIZUMAB USE ON DISABILITY
Statistically significant benefits of natalizumab use on disability were not found in this data set. The mean (median) changes in EDSS at 2 years were 0.03 (0.0) for natalizumab and 0.60 (0.50) for placebo (P=.22). The estimated hazard ratios were 0.789 (95% confidence interval, 0.283-2.199; P=.65) for time to 12-week sustained disability progression and 0.578 (95% confidence interval, 0.105-3.170; P=.53) for time to 24-week sustained disability progression. The large confidence intervals and nonsignificant P values do not allow any definite conclusions about an effect on disability over 2 years and are anticipated owing to the small sample size.
DEVELOPMENT OF ANTIBODIES TO NATALIZUMAB THERAPY
One patient in the natalizumab-treated group was persistently positive for antinatalizumab antibodies during the course of treatment. This patient experienced disability progression (at 12 weeks and at 24 week), had the largest change in EDSS at 2 years (3.0 points), and demonstrated the most relapses (n=4), gadolinium-enhancing lesions (n=3), and new or enlarged T2-weighted lesions (n=10) among patients of African descent in the natalizumabtreated group over 2 years.
SAFETY
Among 49 patients, 100% (28 of 28) of placebo and 95% (20 of 21) of natalizumab-treated patients reported at least 1 adverse event. Blurred vision was reported by 29% (6 of 21) of natalizumab-treated patients vs no placebo patients. Table 4 gives adverse events experienced by at least 5 patients in either study group. The overall incidence of adverse events among this subpopulation was similar to that among the overall study populations.
8-10

COMMENT
Patients of African descent typically exhibit a more aggressive course of MS characterized by rapid progression of disability, more frequent relapses, and worse postrelapse recoveries. Little research on treatment in this population has been reported. The limited available data suggest that this patient population does not seem to respond to treatment with interferon beta as robustly as their counterparts of white race/ethnicity; however, it is unclear whether the observed reduced response is due to a treatment effect or differences in the natural history of the disease. a In the AFFIRM trial, there were 932 patients of non-African descent with the following self-identified races/ethnicities: white (n = 988), Hispanic (n = 13), other (n = 9), Asian (n = 6), and missing (n=5).
b In the SENTINEL trial, there were 1132 patients of non-African descent with the following self-identified races/ethnicities: white (n = 1092), Hispanic (n=22), other (n = 12), Asian (n=6), and missing (n=5). 
